[A12] Goat Anti-Human Apolipoprotein CIII Polyclonal Antibody, Academy Bio-medical Company, Inc.

[A12] Goat Anti-Human Apolipoprotein CIII Polyclonal Antibody

33A-G2

Academy Bio-Medical Company, Inc.

  • $1,167.00


Host Species: Goat
Concentration: 1 mg/ml (OD 1.35 / 280 nm)
Antigen: Human Apolipoprotein CIII
Purification: Affinity purified
Buffer: 75 mM Sodium Phosphate, 75 mM NaCl, 0.5 mM EDTA, 0.02% NaN3, pH 7.2
Specificity Specifically binds to human apo CIII. Dilution for immunoblot and ELISA range: 1,000 to 40,000.
Use: The antibody can be used for detection of apo CIII in plasma and lipoproteins, immunoassays, immunoblots, enzyme conjugation, or biotinylation.
Storage: -20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing.

 

*These products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.

Importance

Apo CIII contains 79 amino acid residues. The m.w. is 8.7 kDa (Brewer et al., 1974).

It may inhibit the activation of lipoprotein lipase by apo CIII. Apo CIII is a constituent of both apoB- and apoAI-containing lipoproteins in the circulation. Apo CIII plays a pivotal role in regulating the plasma metabolism of VLDL, IDL, and LDL, primarily by inhibiting receptor-mediated uptake of these lipoproteins by the liver (Sehayek and Eisenberg 1991, Aalto-Setala et al., 1992, Zheng et al., 2007)

Brewer, H. B., R. Shulman, P. Herbert, R. Ronan, and K. Wehrly. “The complete amino acid sequence of alanine apolipoprotein (apoC-3), and apolipoprotein from human plasma very low density lipoproteins.” J Biol Chem 249.15 (1974):4975-84.

Sehayek , E. , and S. Eisenberg . “Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.” J. Biol. Chem. 266 (1991) : 18259 – 18267 .

Aalto-Setala , K., E. A. Fisher , X. Chen , T. Chajek-Shaul , T. Hayek , R. Zechner , A. Walsh , R. Ramakrishnan , H. N. Ginsberg , and J. L. Breslow . “ Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.” J. Clin. Invest. 90 (1992): 1889 – 1900.

Zheng , C. , C. Khoo , K. Ikewaki , and F. M. Sacks . “ Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions.” J. Lipid Res. 48 (2007): 1190 -203.

 

Citations

[A12][A13] 2018 Aroner, Sarah A.; Koch, Manja; Mukamal, Kenneth J.; Furtado, Jeremy D.; Stein, James H.; Tattersall, Matthew C. et al. (2018): High‐Density Lipoprotein Subspecies Defined by Apolipoprotein C‐III and Subclinical Atherosclerosis Measures: MESA (The Multi‐Ethnic Study of Atherosclerosis). In Journal of the American Heart Association 7 (6), p. 40. DOI: 10.1161/JAHA.117.007824.
[A12][A13] 2018 Furtado, Jeremy D.; Yamamoto, Rain; Melchior, John T.; Andraski, Allison B.; Gamez-Guerrero, Maria; Mulcahy, Patrick et al. (2018): Distinct Proteomic Signatures in 16 HDL (High-Density Lipoprotein) Subspecies. In Arterioscler Thromb Vasc Biol. 38 (12), pp. 2827–2842. DOI: 10.1161/ATVBAHA.118.311607.
[A12][A13] 2018 Kim, KyeongJin; Goldberg, Ira J.; Graham, Mark J.; Sundaram, Meenakshi; Bertaggia, Enrico; Lee, Samuel X. et al. (2018): γ-Secretase Inhibition Lowers Plasma Triglyceride-Rich Lipoproteins by Stabilizing the LDL Receptor. In Cell metabolism 27 (4), 816-827.e4. DOI: 10.1016/j.cmet.2018.02.010.
[A12][A13] 2018 Koch, Manja; DeKosky, Steven T.; Fitzpatrick, Annette L.; Furtado, Jeremy D.; Lopez, Oscar L.; Kuller, Lewis H. et al. (2018): Apolipoproteins and Alzheimer's pathophysiology. In Alzheimer's & dementia (Amsterdam, Netherlands) 10, pp. 545–553. DOI: 10.1016/j.dadm.2018.07.001.
[A12][A13] 2018 Morton, Allyson M.; Koch, Manja; Mendivil, Carlos O.; Furtado, Jeremy D.; Tjønneland, Anne; Overvad, Kim et al. (2018): Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk. In JCI insight 3 (4). DOI: 10.1172/jci.insight.98045.
[A12][A13] 2017 Koch, Manja; Furtado, Jeremy D.; Falk, Kim; Leypoldt, Frank; Mukamal, Kenneth J.; Jensen, Majken K. (2017): Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma. In Alzheimer's & dementia (Amsterdam, Netherlands) 6, pp. 182–187. DOI: 10.1016/j.dadm.2017.01.007.
[A12][A13] 2017 Lee, Chan Joo; Choi, Seungbum; Cheon, Dong Huey; Kim, Kyeong Yeon; Cheon, Eun Jeong; Ann, Soo-jin et al. (2017): Effect of two lipid-lowering strategies on high-density lipoprotein function and some HDL-related proteins: a randomized clinical trial. In Lipids Health Dis 16 (1), p. 49. DOI: 10.1186/s12944-017-0433-6.
[A12][A13] 2017 Sundaram, Meenakshi; Curtis, Kaitlin R.; Amir Alipour, Mohsen; LeBlond, Nicholas D.; Margison, Kaitlyn D.; Yaworski, Rebecca A. et al. (2017): The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation. In Journal of lipid research 58 (11), pp. 2188–2196. DOI: 10.1194/jlr.M077313.
[A12][A13] 2017 Wassef, Hanny; Bissonnette, Simon; Dufour, Robert; Davignon, Jean; Faraj, May (2017): Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women. In J. Nutr. 147 (5), pp. 754–762. DOI: 10.3945/jn.116.242750.
[A12][A13] 2016 Koska, Juraj; Yassine, Hussein; Trenchevska, Olgica; Sinari, Shripad; Schwenke, Dawn C.; Yen, Frances T. et al. (2016): Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes. In Journal of lipid research 57 (5), pp. 894–905. DOI: 10.1194/jlr.P064816.
[A12][A13] 2015 Trenchevska, Olgica; Schaab, Matthew R.; Nelson, Randall W.; Nedelkov, Dobrin (2015): Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms. In Methods (San Diego, Calif.) 81, pp. 86–92. DOI: 10.1016/j.ymeth.2015.02.020.
[A12][A13] 2015 Yassine, Hussein N.; Trenchevska, Olgica; Ramrakhiani, Ambika; Parekh, Aarushi; Koska, Juraj; Walker, Ryan W. et al. (2015): The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides. In PLoS ONE 10 (12), e0144138. DOI: 10.1371/journal.pone.0144138.
[A12][A13] 2014 Lee, An-Sheng; Chen, Wei-Yu; Chan, Hua-Chen; Hsu, Jing-Fang; Shen, Ming-Yi; Chang, Chia-Ming et al. (2014): Gender disparity in LDL-induced cardiovascular damage and the protective role of estrogens against electronegative LDL. In Cardiovascular diabetology 13, p. 64. DOI: 10.1186/1475-2840-13-64.
[A12][A13] 2014 Talayero, Beatriz; Wang, Liyun; Furtado, Jeremy; Carey, Vincent J.; Bray, George A.; Sacks, Frank M. (2014): Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease. In J. Lipid Res. 55 (10), pp. 2167–2177. DOI: 10.1194/jlr.M042333.
[A12][A13] 2014 Wang, Liyun; Sacks, Frank M.; Furtado, Jeremy D.; Ricks, Madia; Courville, Amber B.; Sumner, Anne E. (2014): Racial differences between African-American and white women in insulin resistance and visceral adiposity are associated with differences in apoCIII containing apoAI and apoB lipoproteins. In Nutrition & metabolism 11 (1), p. 56. DOI: 10.1186/1743-7075-11-56.
[A12][A13] 2013 Sumner, Anne E.; Furtado, Jeremy D.; Courville, Amber B.; Ricks, Madia; Younger-Coleman, Novie; Tulloch-Reid, Marshall K.; Sacks, Frank M. (2013): ApoC-III and visceral adipose tissue contribute to paradoxically normal triglyceride levels in insulin-resistant African-American women. In Nutrition & metabolism 10 (1), p. 73. DOI: 10.1186/1743-7075-10-73.
[A12][A13] 2013 Zheng, Chunyu; Azcutia, Veronica; Aikawa, Elena; Figueiredo, Jose-Luiz; Croce, Kevin; Sonoki, Hiroyuki et al. (2013): Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. In European Heart Journal 34 (8), pp. 615–624. DOI: 10.1093/eurheartj/ehs271.
[A12][A13] 2012 Jensen, Majken K.; Rimm, Eric B.; Furtado, Jeremy D.; Sacks, Frank M. (2012): Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease. In Journal of the American Heart Association 1 (2). DOI: 10.1161/JAHA.111.000232.
[A12][A13] 2012 Krauss, Ronald M.; Wojnooski, Kathleen; Orr, Joseph; Geaney, J. Casey; Pinto, Cathy Anne; Liu, Yang et al. (2012): Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. In J. Lipid Res. 53 (3), pp. 540–547. DOI: 10.1194/jlr.M018010.
[A12][A13] 2012 Wada, Yoshinao; Kadoya, Machiko; Okamoto, Nobuhiko (2012): Mass spectrometry of apolipoprotein C-III, a simple analytical method for mucin-type O-glycosylation and its application to an autosomal recessive cutis laxa type-2 (ARCL2) patient. In Glycobiology 22 (8), pp. 1140–1144. DOI: 10.1093/glycob/cws086.
[A12][A13] 2011 Holmberg, R.; Refai, E.; Hoog, A.; Crooke, R. M.; Graham, M.; Olivecrona, G. et al. (2011): Lowering apolipoprotein CIII delays onset of type 1 diabetes. In J. Biol. Chem. 108 (26), pp. 10685–10689. DOI: 10.1073/pnas.1019553108.
[A12][A13] 2011 Mendivil, Carlos O.; Rimm, Eric B.; Furtado, Jeremy; Chiuve, Stephanie E.; Sacks, Frank M. (2011): Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. In Circulation 124 (19), pp. 2065–2072. DOI: 10.1161/CIRCULATIONAHA.111.056986.
[A12][A13] 2011 Qin, Wen; Sundaram, Meenakshi; Wang, Yuwei; Zhou, Hu; Zhong, Shumei; Chang, Chia-Ching et al. (2011): Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen. In J. Biol. Chem. 286 (31), pp. 27769–27780. DOI: 10.1074/jbc.M110.203679.
[A12][A13] 2010 Furtado, Jeremy D.; Campos, Hannia; Sumner, Anne E.; Appel, Lawrence J.; Carey, Vincent J.; Sacks, Frank M. (2010): Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial. In The American journal of clinical nutrition 92 (4), pp. 714–722. DOI: 10.3945/ajcn.2009.28532.
[A12][A13] 2010 Jayanthi, S.; Buie, S.; Moore, S.; Herning, R. I.; Better, W.; Wilson, N. M. et al. (2010): Heavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analyses. In Molecular psychiatry 15 (1), pp. 101–112. DOI: 10.1038/mp.2008.50;
[A12][A13] 2010 Sundaram, Meenakshi; Zhong, Shumei; Bou Khalil, Maroun; Zhou, Hu; Jiang, Zhenghui G.; Zhao, Yang et al. (2010): Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia. In J. Lipid Res. 51 (6), pp. 1524–1534. DOI: 10.1194/jlr.M005108.
[A12][A13] 2010 Sundaram, Meenakshi; Zhong, Shumei; Khalil, Maroun Bou; Links, Philip H.; Zhao, Yang; Iqbal, Jahangir et al. (2010): Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. In J. Lipid Res. 51 (1), pp. 150–161. DOI: 10.1194/jlr.M900346-JLR200.
[A12][A13] 2008 Deng, Ting; Ji, Wei; Lian, Ji-Hong; Guo, Lei; Hu, Wei-Rong; Qian, Ming; Gong, Bang-qiang (2008): Identifying Natural Derived Upregulators of Human ApoA-I Expression via a Cell-Based Drug Screening System. In Pharmaceutical Biology 46 (9), pp. 610–615. DOI: 10.1080/13880200802179584.
[A12][A13] 2008 Furtado, Jeremy D.; Campos, Hannia; Appel, Lawrence J.; Miller, Edgar R.; Laranjo, Nancy; Carey, Vincent J.; Sacks, Frank M. (2008): Effect of protein, unsaturated fat, and carbohydrate intakes on plasma apolipoprotein B and VLDL and LDL containing apolipoprotein C-III: results from the OmniHeart Trial. In The American journal of clinical nutrition 87 (6), pp. 1623–1630. DOI: 10.1093/ajcn/87.6.1623.
[A12][A13] 2008 Ruiz-Narváez, Edward A.; Sacks, Frank M.; Campos, Hannia (2008): Abdominal obesity and hyperglycemia mask the effect of a common APOC3 haplotype on the risk of myocardial infarction. In The American journal of clinical nutrition 87 (6), pp. 1932–1938. DOI: 10.1093/ajcn/87.6.1932.
[A12][A13] 2007 Kawakami, Akio; Aikawa, Masanori; Nitta, Noriko; Yoshida, Masayuki; Libby, Peter; Sacks, Frank M. (2007): Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation. In Arterioscler Thromb Vasc Biol. 27 (1), pp. 219–225. DOI: 10.1161/01.ATV.0000249620.68705.0d.
[A12][A13] 2007 Gaubatz, John W.; Gillard, Baiba K.; Massey, John B.; Hoogeveen, Ron C.; Huang, Max; Lloyd, Eric E. et al. (2007): Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2). In J. Lipid Res. 48 (2), pp. 348–357. DOI: 10.1194/jlr.M600249-JLR200.
[A12][A13] 2006 Guo, Lei; Hu, Wei-Rong; Lian, Ji-Hong; Ji, Wei; Deng, Ting; Qian, Ming; Gong, Bang-qiang (2006): Anti-hyperlipidemic properties of CM108 (a flavone derivative) in vitro and in vivo. In European journal of pharmacology 551 (1-3), pp. 80–86. DOI: 10.1016/j.ejphar.2006.08.048.
[A12][A13] 2006 Kawakami, Akio; Aikawa, Masanori; Alcaide, Pilar; Luscinskas, Francis W.; Libby, Peter; Sacks, Frank M. (2006): Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. In Circulation 114 (7), pp. 681–687. DOI: 10.1161/CIRCULATIONAHA.106.622514.
[A12][A13] 2006 Kawakami, Akio; Aikawa, Masanori; Libby, Peter; Alcaide, Pilar; Luscinskas, Francis W.; Sacks, Frank M. (2006): Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. In Circulation 113 (5), pp. 691–700. DOI: 10.1161/CIRCULATIONAHA.105.591743.
[A12][A13] 2006 Schaap, Frank G.; Nierman, Melchior C.; Berbée, Jimmy F. P.; Hattori, Hiroaki; Talmud, Philippa J.; Vaessen, Stefan F. C. et al. (2006): Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. In J. Lipid Res. 47 (10), pp. 2333–2339. DOI: 10.1194/jlr.M500533-JLR200.
[A12][A13] 2005 Nedelkov, Dobrin; Kiernan, Urban A.; Niederkofler, Eric E.; Tubbs, Kemmons A.; Nelson, Randall W. (2005): Investigating diversity in human plasma proteins. In Proc Natl Acad Sci USA 102 (31), pp. 10852–10857. DOI: 10.1073/pnas.0500426102.
[A12][A13] 2004 Juntti-Berggren, Lisa; Refai, Essam; Appelskog, Ioulia; Andersson, Mats; Imreh, Gabriela; Dekki, Nancy et al. (2004): Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes. In Proc Natl Acad Sci USA 101 (27), pp. 10090–10094. DOI: 10.1073/pnas.0403551101.
[A12][A13] 2003 Malek, Goldis; Li, Chuan-Ming; Guidry, Clyde; Medeiros, Nancy E.; Curcio, Christine A. (2003): Apolipoprotein B in Cholesterol-Containing Drusen and Basal Deposits of Human Eyes with Age-Related Maculopathy. In The American Journal of Pathology 162 (2), pp. 413–425. DOI: 10.1016/S0002-9440(10)63836-9.
[A12][A13] 2003 Yang, Chao-Yuh; Raya, Joe L.; Chen, Hsin-Hung; Chen, Chu-Huang; Abe, Yasunori; Pownall, Henry J. et al. (2003): Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins. In Arterioscler Thromb Vasc Biol. 23 (6), pp. 1083–1090. DOI: 10.1161/01.ATV.0000071350.78872.C4.
[A12][A13] 2001 Deeg, M. A.; Bierman, E. L.; Cheung, M. C. (2001): GPI-specific phospholipase D associates with an apoA-I- and apoA-IV-containing complex. In J. Lipid Res. 42 (3), pp. 442–451.

We Also Recommend